Hugel, Inc. 145020

Hugel Inc., a leading global medical aesthetics company publicly traded in South Korea, is accelerating its global skincare expansion by bringing its clinical cosmetics WELLAGE to Sephora, one of the world's leading beauty retailers. Through a strategic partnership with OLIVE YOUNG, Korea's leading beauty and lifestyle retailer, WELLAGE has officially entered the North American market.

Hugel Inc., a leading global medical aesthetics company publicly traded in South Korea, today announced record first-half financial results, with consolidated net sales, operating profit, and net income reaching all-time highs, primarily driven by solid demand for botulinum toxin.

Hugel Aesthetics today announced a major expansion of its U.S. business, marking the next phase of the company's long-term growth strategy. The expansion includes the launch of a dedicated direct sales and field-based medical affairs organization for the #1 best-selling neurotoxin in South Korea for 10 years1, Letybo® (letibotulinumtoxinA-wlbg), and investments in a new consumer K-TOX campaign, medical congress support and clinical evidence generation.

Hugel, Inc., a leading global medical aesthetics company publicly traded in South Korea, reinforced its position in the global aesthetics market by showcasing its scientific expertise, educational leadership and expanding global network at the Aesthetic & Anti-aging Medicine World Congress Korea (AMWC KOREA), held on June 19–20 at Grand InterContinental Seoul Parnas.

Hugel, a leading global medical aesthetics company publicly traded in South Korea, reaffirmed its ambition to strengthen its leadership in the global aesthetics industry. The company said the Korean approach to aesthetics — centered on natural-looking results, balance, and rapid innovation — is setting new standards worldwide and supporting Hugel's international expansion.

Hugel Inc., a leading global medical aesthetics company publicly traded in South Korea, has delivered record consolidated results for the first quarter. On Thursday, the company reported net sales of KRW116.6 billion, operating profit of KRW47.6 billion, and net profit of KRW40.6 billion for the January–March period this year, representing on-year increases of 29.9%, 22.3%, and 31.5%, respectively.

Hugel Inc., a leading global medical aesthetics company publicly traded in South Korea, has accelerated its growth strategy by adding an extracellular matrix (ECM)-based injectable treatment to its portfolio.

Hugel Inc., a leading global medical aesthetics company publicly traded in South Korea, announced preliminary consolidated financial results for 2025 with KRW425.1 billion in net sales, KRW201.6 billion in operating profit, and KRW144 billion in net profit. The results represent the highest in the company's history, reflecting on-year increases of 14%, 21.3%, and 0.6%, respectively.